Sort   by:  
 Page size 
MetabolomicsMicrobiome Metabolism of Dietary Phytochemicals Controls the Anticancer Activity of PI3K Inhibitors
Phosphatidylinositol 3-kinase (PI3K) signaling is both the effector pathway of insulin and among the most frequently activated pathways in human cancer. In murine cancer models, the efficacy of PI3K inhibitors is dramatically enhanced by a ketogenic diet, with a proposed mechanism involving dietary ...
2025-03-26 | MTBLS10944 | MetaboLights
MetabolomicsMirabegron displays anticancer effects by globally browning adipose tissues

Metabolic reprogramming in malignant cells is a hallmark of cancer that relies on augmented glycolytic metabolism to support their growth, invasion and metastasis. However, the impact of global adipose metabolism on tumor growth and the drug development by targeting adipose metabolism remain larg...

2023-11-08 | MTBLS8682 | MetaboLights
MetabolomicsThe anticancer human mTOR inhibitor MLN0128/Sapanisertib with potent multistage in vitro antiplasmodium activity and in vivo antimalarial efficacy in a humanised mouse model is an inhibitor of multiple Plasmodium falciparum kinases.
Not available
ORGANISM(S): Plasmodium falciparum 
ST002011 | MetabolomicsWorkbench
GenomicsAnticancer activity of RAS-GTP inhibition in cholangiocarcinoma [Mouse_iAKP_Abr24]
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma [Mouse_iAKP_Abr24]
PRJNA1418665 | ENA
GenomicsAnticancer activity of RAS-GTP inhibition in cholangiocarcinoma [Human_Abr24]
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma [Human_Abr24]
PRJNA1418666 | ENA
GenomicsAnticancer activity of RAS-GTP inhibition in cholangiocarcinoma [Mouse_hKPR.KPCHR_Sep25]
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma [Mouse_hKPR.KPCHR_Sep25]
PRJNA1418668 | ENA
GenomicsAnticancer activity of RAS-GTP inhibition in cholangiocarcinoma
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma
PRJNA1418659 | ENA
TranscriptomicsDifferential gene expression for A2780 human ovarian cancer cells when exposed to a new osmium-based anticancer agent
Platinum-based metallodrugs are the most widely used anticancer agents. Their reduced effectiveness after repeat dosing (resistance) constitutes a major clinical problem. In this experiment we study a potent organo-osmium compound with improved activity over cisplatin and no cross-resistance in plat...
ORGANISM(S): Homo sapiens 
2016-05-22 | E-MTAB-2758 | biostudies-arrayexpress
ProteomicsProteomics analysis of Polyphyllin D-treated triple-negative breast cancer cells reveal the anticancer mechanisms of Polyphyllin D
Polyphyllin D (PD) is the active component from an Asian traditional medicinal herb Paris polyphylla, and has been found to hold significant anticancer activity in vivo or in vitro. However, the mechanism through which PD exerts its anticancer effects in triple-negative breast cancer (TNBC) remains ...
ORGANISM(S): Homo Sapiens 
2023-03-20 | PXD040990 |
TranscriptomicsCombined PI3K/mTOR and MEK Inhibition Provides Broad Anti-Tumor Activity in Faithful Murine Cancer Models
Anticancer drug development is an inefficient process, with potential therapeutics demonstrating a high attrition rate due to lack of efficacy in Phase II/III testing. In an effort to develop improved pre-clinical predictors of efficacy, we and others have turned to testing in genetically engineere...
ORGANISM(S): Mus musculus 
2012-08-21 | E-GEOD-35722 | biostudies-arrayexpress
Sort   by:  
 Page size